Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l